Candel Therapeutics (CADL) Other Accumulated Expenses (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Other Accumulated Expenses data on file, last reported at $89000.0 in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses fell 77.18% year-over-year to $89000.0; the trailing twelve-month figure through Dec 2025 stood at $89000.0 (down 77.18% YoY), and the FY2025 full-year result was $89000.0, down 77.18% from the prior year.
• Other Accumulated Expenses climbed to $89000.0 in Q4 2025, from $55000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $400000.0 in Q4 2023 to a low of $31000.0 in Q3 2022.
• A 5-year average of $167437.5 and a median of $91500.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses slumped 86.46% in 2022 and jumped 733.33% in 2023, its largest moves.
• Tracing CADL's Other Accumulated Expenses over 5 years: stood at $334000.0 in 2021, then plunged by 85.63% to $48000.0 in 2022, then jumped by 733.33% to $400000.0 in 2023, then dropped by 2.5% to $390000.0 in 2024, then plunged by 77.18% to $89000.0 in 2025.
• Business Quant data shows CADL's Other Accumulated Expenses at $89000.0 in Q4 2025, $55000.0 in Q3 2025, and $266000.0 in Q2 2025.